• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

    9/17/24 11:22:47 AM ET
    $AZN
    $BLTE
    $HCM
    $IH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email

    NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, September 24 and Wednesday, September 25, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US.

    Representatives from participating companies based in China, France, Hong Kong, Netherlands, Philippines, Portugal, Spain, Switzerland, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies.

    There is no fee for participants to log in, attend live presentations and/or ask questions.

    Pre-registration is suggested. Please register here: www.adr.db.com/dbvic

    September 24 Agenda (US Eastern Standard Time):

    • 8:00 AM: First Pacific Company Ltd ((HKEX: 142, OTC:FPAFY)
    • 8:30 AM: Lotus Technology Inc (NASDAQ:LOT)
    • 9:00 AM: HUTCHMED (China) Limited ((AIM: HCM, NASDAQ:HCM, and HKEX:13))
    • 9:30 AM: iHuman Inc. (NYSE:IH)
    • 10:00 AM: Marks and Spencer ((LSE: MKS, OTC:MAKSY)
    • 10:30 AM: SSE plc ((LSE: SSE, OTC:SSEZY)
    • 11:00 AM: BDO Unibank, Inc ((PSE: BDO, OTC:BDOUY)
    • 11:30 AM: AstraZeneca plc ((LSE: AZN, NASDAQ:AZN)

    September 25 Agenda (US Eastern Standard Time):

    • 8:00 AM: Yiren Digital Ltd (NYSE:YRD)
    • 8:30 AM: KPN ((Euronext Amsterdam: KPN, OTC:KKPNY)
    • 9:00 AM: Viomi Technology Co., Ltd (NASDAQ:VIOT)
    • 9:30 AM: Carrefour S.A. (PARIS:CA, OTC:CRRFY)
    • 10:00 AM: EDP Group ((Euronext Lisbon: EDP, OTC:EDPFY)
    • 10:30 AM: Repsol S.A ((BMAD: REP, OTC:REPYY)
    • 11:00 AM: Belite Bio, Inc  (NASDAQ:BLTE)
    • 11:30 AM: DSM-Firmenich AG ((DSFIR:AEX, OTC:DSFIY)

    The presentations will be available for replay after the Conference.

    In addition to specializing in administering cross-border equity structures such as American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. The Bank offers a broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

    For further information, please contact:

    Dylan Riddle

    Deutsche Bank AG

    Press & Media Relations

    Tel. +12122504982

    Cell. +1(904)3866481

    Email [email protected]

    Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany's leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

    Deutsche Bank is sponsoring the Deutsche Bank Depositary Receipt Investor Conference solely for informational purposes. Deutsche Bank does not prepare, review, approve or edit any presentations, statements, documents or other information or materials, whether in written, electronic or verbal form, provided by any company participating in such conference, and disclaims any responsibility for the accuracy or adequacy of any such information or materials. Deutsche Bank is not promoting, endorsing or recommending any company participating in the conference.

    The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© September 2024 Deutsche Bank AG. All rights reserved.



    Primary Logo

    Get the next $AZN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AZN
    $BLTE
    $HCM
    $IH

    CompanyDatePrice TargetRatingAnalyst
    HUTCHMED (China) Limited
    $HCM
    5/13/2025Buy → Hold
    HSBC Securities
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    AstraZeneca PLC
    $AZN
    2/12/2025Overweight
    Morgan Stanley
    AstraZeneca PLC
    $AZN
    11/20/2024Sell → Neutral
    UBS
    AstraZeneca PLC
    $AZN
    11/6/2024Sell → Hold
    Deutsche Bank
    AstraZeneca PLC
    $AZN
    9/13/2024Hold → Sell
    Deutsche Bank
    AstraZeneca PLC
    $AZN
    5/30/2024$97.00Buy
    Goldman
    More analyst ratings

    $AZN
    $BLTE
    $HCM
    $IH
    SEC Filings

    See more
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      7/14/25 10:30:50 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Viomi Technology Co. Ltd

      6-K - Viomi Technology Co., Ltd (0001742770) (Filer)

      7/14/25 9:20:55 AM ET
      $VIOT
      Consumer Electronics/Appliances
      Consumer Discretionary
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      7/7/25 6:24:13 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    $BLTE
    $HCM
    $IH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viomi Technology Co., Ltd Announces Declaration of a Special Dividend

      GUANGZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ:VIOT), a leading technology company for home water solutions in China, today announced that its board of directors has approved the declaration and distribution of a special dividend (the "Special Dividend") of US$0.0293 per ordinary share (US$0.0880 per American depositary share, or ADS). The aggregate amount of the Special Dividend will be approximately US$6 million. The Special Dividend is expected to be paid on or around August 18, 2025 to the holders of the Company's ordinary shares, and on or around August 21, 2025 to the holders of the Company's ADSs, of record, as of the

      7/14/25 7:45:42 AM ET
      $VIOT
      Consumer Electronics/Appliances
      Consumer Discretionary
    • Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension

      Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated with a favorable safety profile. There are 1.3 billion people worldwide livin

      7/14/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED to Announce 2025 Half-Year Financial Results

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 03, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2025 on Thursday, August 7, 2025 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT). HUTCHMED management will host two webcast presentations for analysts and investors to discuss the interim results, followed by Q&A sessions. The English webcast will be held on Thursday, August 7, 2025, at 8:00 am EDT (1:00 pm BST / 8:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 1:30 am BST on Friday

      7/3/25 4:30:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    $BLTE
    $HCM
    $IH
    Financials

    Live finance-specific insights

    See more
    • Viomi Technology Co., Ltd Announces Declaration of a Special Dividend

      GUANGZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ:VIOT), a leading technology company for home water solutions in China, today announced that its board of directors has approved the declaration and distribution of a special dividend (the "Special Dividend") of US$0.0293 per ordinary share (US$0.0880 per American depositary share, or ADS). The aggregate amount of the Special Dividend will be approximately US$6 million. The Special Dividend is expected to be paid on or around August 18, 2025 to the holders of the Company's ordinary shares, and on or around August 21, 2025 to the holders of the Company's ADSs, of record, as of the

      7/14/25 7:45:42 AM ET
      $VIOT
      Consumer Electronics/Appliances
      Consumer Discretionary
    • Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension

      Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated with a favorable safety profile. There are 1.3 billion people worldwide livin

      7/14/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iHuman Inc. Announces First Quarter 2025 Unaudited Financial Results

      BEIJING, June 26, 2025 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Revenues were RMB210.4 million (US$29.0 million), compared with RMB235.0 million in the same period last year.Gross profit was RMB143.8 million (US$19.8 million), compared with RMB168.1 million in the same period last year.Operating income was RMB21.6 million (US$3.0 million), compared with

      6/26/25 6:12:00 AM ET
      $IH
      Other Consumer Services
      Real Estate

    $AZN
    $BLTE
    $HCM
    $IH
    Leadership Updates

    Live Leadership Updates

    See more
    • Lotus Technology Announces Management and Board Changes

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Lotus Technology Inc. ("Lotus" or the "Company") (NASDAQ:LOT), a leading global intelligent and luxury mobility provider, today announced changes to its management team and board of directors. The board of directors of the company (the "Board") has approved the appointment of Mr. Daxue Wang as the Chief Financial Officer ("CFO") of the Company effective April 8, 2025. Mr. Wang is a seasoned executive across corporate and prominent financial institutions, most recently serving as CFO of Radar Auto. Prior to that, Mr. Wang held several executive positions in Zhejiang Kangsheng, Huzhou Moshan Asset Management, Morgan Stanley Securities, ICBC Credi

      4/8/25 4:30:00 PM ET
      $LOT
    • HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independent Non-executive Director and a member of the Audit Committee of the Company with effect from March 6, 2025. Mr Wong has over 35 years of extensive experience in accounting, auditing and corporate finance. He has acted in a pivotal role in assisting companies with their stock exchange listings and has been instrumental in completing numerous mergers and acquisitions. After a distinguished career spanning more than three decades, Mr Wong retired as

      3/5/25 5:00:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viomi Technology Co., Ltd Appoints New President of Operations to Promote High-quality Business Development

      GUANGZHOU, China, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ:VIOT), a leading technology company for home water solutions in China, today announced the appointment of Mr. Guang Wu as President of Operations, effective December 4, 2024. In this role, Mr. Wu will focus on driving high-quality business development and enhancing operational efficiency. Mr. Wu brings over 20 years of experience in business development and marketing within the domestic home appliances and home furnishing industry. Prior to joining Viomi, he served as Vice President and General Manager of Domestic Marketing at Sleemon Group. Before that, he managed domestic m

      12/4/24 4:00:00 AM ET
      $VIOT
      Consumer Electronics/Appliances
      Consumer Discretionary

    $AZN
    $BLTE
    $HCM
    $IH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HUTCHMED downgraded by HSBC Securities

      HSBC Securities downgraded HUTCHMED from Buy to Hold

      5/13/25 3:20:36 PM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

      Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

      4/15/25 12:40:56 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AstraZeneca upgraded by UBS

      UBS upgraded AstraZeneca from Neutral to Buy

      2/13/25 8:39:12 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    $BLTE
    $HCM
    $IH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Viomi Technology Co. Ltd

      SC 13G/A - Viomi Technology Co., Ltd (0001742770) (Subject)

      11/12/24 6:35:53 AM ET
      $VIOT
      Consumer Electronics/Appliances
      Consumer Discretionary
    • SEC Form SC 13G filed by Lotus Technology Inc.

      SC 13G - Lotus Technology Inc. (0001962746) (Subject)

      11/12/24 6:07:58 AM ET
      $LOT
    • SEC Form SC 13G filed by Lotus Technology Inc.

      SC 13G - Lotus Technology Inc. (0001962746) (Subject)

      11/8/24 6:04:35 AM ET
      $LOT